|
Age, median (IQR)
|
31.0 (25-34)
|
26.0 (20-30.25)
|
0.028
|
|
Sex
|
|
Male
|
29 (74.4%)
|
14 (46.7%)
|
0.019
|
|
Female
|
10 (25.6%)
|
16 (53.3%)
| |
|
Montreal classification
|
|
Age at onset
|
|
A1 (≤16yr)
|
15 (38.5%)
|
6 (20.0%)
|
0.098
|
|
A2 (17-40yr)
|
24 (61.5%)
|
24 (80.0%)
| |
|
A3 (≥41yr)
|
0 (0.0%)
|
0 (0.0%)
| |
|
Location
|
|
L1 (Ileum)
|
4 (10.3%)
|
8 (26.7%)
|
0.171
|
|
L2 (Colon)
|
3 (7.7%)
|
3 (10.0%)
| |
|
L3 (Ileocolon)
|
32 (82.1%)
|
19 (63.3%)
| |
|
Behavior
|
|
B1 (Non-stricturing, non-penetrating)
|
12 (30.8%)
|
20 (66.7%)
|
0.002
|
|
B2 (Stricturing)
|
6 (15.4%)
|
6 (20.0%)
| |
|
B3 (Penetrating)
|
21 (53.8%)
|
4 (13.3%)
| |
|
Albumin, mean±SD (g/dL)
|
3.36±0.48
|
4.05±0.42
|
<0.001
|
|
CRP, mean±SD (mg/dL)
|
3.03±3.04
|
0.56±0.74
|
<0.001
|
|
Fistula type
|
|
Simple
|
13 (33.3%)
|
6 (20.0%)
|
0.219
|
|
Complex
|
26 (66.7%)
|
24 (80.0%)
| |
|
Multiple fistula
|
15 (38.5%)
|
13 (43.3%)
|
0.683
|
|
Proctitis
|
19 (48.7%)
|
10 (33.3%)
|
0.199
|
|
Stricture
|
1 (2.6%)
|
2 (6.7%)
|
0.407
|
|
Abscess
|
18 (46.2%)
|
17 (56.7%)
|
0.387
|
|
Medical treatment
|
|
Immunomodulators
|
16 (41.0%)
|
15 (50.0%)
|
0.458
|
|
Steroids
|
2 (5.2%)
|
0 (0.0%)
|
0.208
|
|
Smoking
|
|
Current smoker
|
4 (10.3%)
|
1 (3.3%)
|
0.355
|
|
Ex-smoker
|
8 (20.5%)
|
4 (13.3%)
| |
|
Previous fistula OP
|
37 (94.9%)
|
30 (100%)
|
0.208
|
|
No. previous fistula OP, mean±SD (times)
|
3.24±1.89
|
2.17±1.29
|
0.010
|
|
Interval from seton treatment to anti-TNF or stem cell therapy, mean±SD (months)
|
1.03±0.93
|
16.13±16.01
|
<0.001
|
|
Disease duration, mean±SD (years)
|
9.37±6.13
|
6.10±4.88
|
0.018
|
